- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Elacestrant – March 2025
Elacestrant; Tablet 86 mg (as dihydrochloride), Tablet 345 mg (as dihydrochloride); Orserdu®
Last updated
12 March 2025